Sponsor Dossier
Hospira
Sponsor Dossier for Hospira. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: Aciclovir
- Brand: ANZATAX
- Brand: Atracurium
- Brand: Calcium
- Brand: Carboplatin
- Brand: Cisplatin
- Brand: DBL
- Brand: Desferoxamine
About
Hospira is an Australian Private Company with ABN 58 097 064 330, registered in Victoria. The entity status is Active. Hospira has traded under several business names, including David Bull Laboratories (from 2007), Mayne Pharma (from 2007), and Pfizer Melbourne (from 2017).
Portfolio
Hospira has 22 brands on the ARTG, of which 3 are indexable and 0 carry a Product Information document. 3 brands are PBS-listed, 0 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include Aciclovir, ANZATAX, Atracurium, Calcium, Carboplatin, Cisplatin, DBL, Desferoxamine, Docetaxel Injection, USP, Doxorubicin, Emblaveo, Gemcitabine IV Infusion.
Therapeutic focus
— Oncology: 14 brands — Infectious Disease: 5 brands — Haematology: 1 brand — Pain Management: 1 brand — Musculoskeletal: 1 brand
PBS footprint
3 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2016-03-01, across 0 brands with a PBAC outcome on record.